HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 294/2/L190    most recent 00277.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Panebra, A. Articles by Liggett, S. B. Search for Related Content PubMed PubMed Citation Articles by Panebra, A. Articles by Liggett, S. B.

EDITORIAL FOCUS

Variable-length poly-C tract polymorphisms of the β₂-adrenergic receptor 3'-UTR alter expression and agonist regulation

¹Cardiopulmonary Genomics Program, University of Maryland School of Medicine, Baltimore, Maryland; ²Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and ³Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina

Submitted 17 July 2007 ; accepted in final form 7 November 2007

β₂-Adrenergic receptors (β₂-AR) expressed on airway epithelial and smooth muscle cells regulate mucociliary clearance and relaxation and are the targets for β-agonists in the treatment of obstructive lung disease. However, the clinical responses display extensive interindividual variability, which is not adequately explained by genetic variability in the 5'-flanking or coding region of the intronless β₂-AR gene. The nonsynonymous coding polymorphism most often associated with a bronchodilator phenotype (Arg16) is found within three haplotypes that differ by the number of Cs (11, 12, or 13) within a 3'-untranslated region (UTR) poly-C tract. To examine potential effects of this variability on receptor expression, BEAS-2B cells were transfected with constructs containing the β₂-AR (Arg16) coding sequence followed by its 3'-UTR with the various polymorphic poly-C tracts. β₂Arg16-11C had 25% lower mRNA expression and 33% lower β₂-AR protein expression compared with the other two haplotypes. Consistent with this lower steady-state expression, β₂Arg16-11C mRNA displayed more rapid and extensive degradation after actinomycin D treatment compared with β₂Arg16-12C and -13C. However, β₂Arg16-12C underwent 50% less downregulation of receptor expression during β-agonist exposure compared with the other two haplotypes. Thus these haplotypes direct a potential low-response phenotype due to decreased steady-state receptor expression combined with wild-type agonist-promoted downregulation (β₂Arg16-11C) and a high-response phenotype due to increased baseline expression combined with decreased agonist-promoted downregulation (β₂Arg16-12C). This heterogeneity may contribute to the variability of clinical responses to β-agonist, and genotyping to identify these 3'-UTR polymorphisms may improve predictive power within the context of β₂-AR haplotypes in pharmacogenetic studies.

asthma; β-agonist; transcription

This article has been cited by other articles:

				P. E. Moore Exploration of the {beta}2-adrenergic receptor regulatory regions: the next step in the holy grail of asthma pharmacogenetics research Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L187 - L189. [Full Text] [PDF]